THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

Stock Information for Lexaria Bioscience Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lexaria Bioscience Corp.

Lexaria Awarded Six Additional Patents
Lexaria Releases Annual Letter from the CEO
Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4
Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
Lexaria Bioscience Corp. Provides Strategic Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.